Sunita D. Nasta, MD
The complexity of the various T-cell lymphomas makes finding a standard treatment for patients with any of the disease subtypes difficult, according to Sunita D. Nasta, MD.
on Hematologic Malignancies, Nasta, an associate professor of clinical medicine at the University of Pennsylvania, compared the biology of peripheral and cutaneous T-cell lymphomas and offered advice on the optimal therapeutic approaches for either disease with novel agents. She also highlighted newer approaches coming down the pipeline.
OncLive: Can you provide an overview of your talk and discuss advancements and progress happening in the field of T-cell lymphoma?
: T-cell lymphoma is a heterogeneous group of disorders. It constitutes about 15% of all non-Hodgkin lymphomas. My talk had 2 parts. One [focused on] peripheral T-cell lymphoma and the other [was about] cutaneous T-cell lymphoma. The approaches are slightly different. Medical oncologists will see early diagnosis of peripheral T-cell lymphoma, and they will [typically] see a later diagnosis of cutaneous T-cell lymphoma.
... to read the full story